Older Men’s Decision Making About Active Surveillance for Prostate Cancer – Aim 3: Decision Aid Efficacy Testing
Conditions
Prostate CancerSummary
This protocol describes pilot testing of an educational shared decision-making intervention to help men with localized prostate cancer make decisions with their health care providers about if and when to de-escalate surveillance testing. The project is important because for many patients their cancer does not progress to the point of needed curative treatment or their health status changes such that they are no longer good candidates for treatment. For these men, de-escalating ongoing surveillance (e.g., fewer biopsies or imaging studies) is a reasonable option.
Detailed Description
Primary Objective:
The overall goal of this protocol is to test initial efficacy of three versions of an educational tool for use by patients and health-care providers to help men with localized prostate cancer make informed decisions about discontinuation of active surveillance. A pre-post design was selected to provide initial efficacy data of the different versions of the shared decision-making intervention. Thereby, providing preliminary data in preparation for a follow-up comparative study.
Locations
1 location Found with status Recruiting
Status
- RECRUITING
Contact Person
- Lisa Lowenstein, MD
- 713-563-0020
- [email protected]
Principal Investigator
- Lisa Lowenstein, MD
Eligibility Criteria
Inclusion Criteria:
Patients:
1. Males aged 65 or older
2. Diagnosis of localized prostate cancer
3. Have not received curative intent treatment for their prostate cancer
4. Fluent in English
Care partners/caregivers:
1. Aged 18 or older
2. Fluent in English
3. Involved with the care of an eligible patient (i.e. partner, close friend, family member, companion)
Exclusion Criteria:
Patients
1. Currently receiving treatment for another cancer (primary or recurrence)
Care partners/caregivers
1. None
Outcome Measures
Primary Outcome Measures
Preparation for Decision Making Scale
Timeline
Last Updated
February 4, 2025Start Date
January 21, 2025Today
May 11, 2025Completion Date ( Estimated )
February 2, 2030
Sponsors of this trial
Lead Sponsor
M.D. Anderson Cancer CenterCollaborating Sponsors
American Cancer Society, Inc.